{"product_id":"scyx-bcg-matrix","title":"(SCYX) SCYNEXIS, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis SCYNEXIS, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The content shown on this page is a real preview of the actual deliverable, so you can review the format and sample insights before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBREXAFEMME VVC label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBREXAFEMME is SCYNEXIS, Inc.'s only marketed product and its clearest commercial growth asset. The U.S.-approved oral ibrexafungerp for vulvovaginal candidiasis gives the company a real women’s health footprint, with a simple 2-dose regimen of 150 mg tablets. In BCG terms, it fits as a Star only if 2025-2026 sales keep scaling from this single brand base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBREXAFEMME recurrent VVC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBREXAFEMME recurrent VVC expands SCYNEXIS, Inc. beyond single-episode treatment into a much larger maintenance market, and that is the main Stars driver in the BCG view. SCYNEXIS has already reported Phase 3 CANDLE data in recurrent vulvovaginal candidiasis, which supports broader use and strengthens the franchise’s near-term growth path. This matters because recurrent VVC affects a far larger pool than isolated infections, so even modest uptake can add meaningful revenue leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIbrexafungerp oral franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBREXAFEMME is SCYNEXIS, Inc.’s commercial ibrexafungerp brand and the clearest \"Star\" in its BCG mix: it is oral, so it fits outpatient care and repeat prescribing, unlike hospital-only IV antifungals. That matters because the labeled regimen uses 300 mg as two 150 mg doses, which supports use in recurrent vulvovaginal candidiasis and broadens addressable demand. The oral format gives it more upside and less site-of-care friction, so growth potential is stronger than a niche inpatient drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFirst-in-class triterpenoid antifungal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIbrexafungerp is a first-in-class triterpenoid antifungal, so SCYNEXIS, Inc. can stand out in a crowded azole market and keep physician attention. Its non-azole mechanism helps support pricing power and a clearer clinical story, especially where resistance limits older drugs. That niche positioning matters because antifungal demand stays steady, but true differentiation is rare.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-in-class, non-azole MOA\u003c\/li\u003e\n\u003cli\u003eSupports pricing and retention\u003c\/li\u003e\n\u003cli\u003eHelps defend physician mindshare\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. vaginal candidiasis market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eU.S. vaginal candidiasis is a large, repeat-use market: CDC says 75% of women get at least one VVC episode, and about 8% to 9% have recurrent VVC. That recurring patient pool matters for SCYNEXIS, because even modest share can support steady brand demand.\u003c\/p\u003e\n\u003cp\u003eSCYNEXIS has its best commercial footing here since recurrent infections drive repeat treatment, not one-time use. The U.S. antifungal market is also price-stable, which helps branded products keep value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e75% lifetime VVC incidence\u003c\/li\u003e\n\u003cli\u003e8% to 9% recurrent VVC\u003c\/li\u003e\n\u003cli\u003eRepeat use supports brand growth\u003c\/li\u003e\n\u003cli\u003eBest SCYNEXIS commercial market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBREXAFEMME Drives SCYNEXIS Growth Outlook\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBREXAFEMME is SCYNEXIS, Inc.’s only real Star because it has the clearest growth runway in 2025-2026. CDC says about 75% of women get VVC and 8%-9% get recurrent VVC, so repeat use can support sales. Phase 3 CANDLE data also strengthens the recurrent-VVC case.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVVC lifetime incidence\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurrent VVC\u003c\/td\u003e\n\u003ctd\u003e8%-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSCYNEXIS BCG Matrix: maps its pipeline by quadrant to pinpoint invest, hold, and divest priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page SCYNEXIS, Inc. BCG Matrix clarifying portfolio pain points at a glance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists the key SCYNEXIS sources in one traceable place, making claims easier to verify and decisions faster to support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBREXAFEMME sales base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBREXAFEMME is SCYNEXIS, Inc.'s only recurring product revenue stream, so it is the clearest internal cash generator in the base. Even with early-stage growth, its repeat sales help fund operating cash needs better than any other company asset, making it the core Cash Cow in the BCG mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck collaboration economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.'s Merck collaboration can throw off non-dilutive cash through upfronts, milestones, or return-of-rights payments, but it is more of a financing bridge than a growth engine. In BCG terms, that makes it a Cash Cow only in the sense of steady support, not big scale; Merck-style deal cash is usually small versus SCYNEXIS, Inc.'s R\u0026amp;D spend and losses. The economics matter, but they do not replace product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHansoh regional rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHansoh regional rights give SCYNEXIS, Inc. China-linked value without a full sales buildout. The deal brought a $4 million upfront payment and can add up to $67 million in milestones, plus tiered royalties, making it one of the few mature cash paths for ibrexafungerp. Regional licensing keeps capital needs low and turns ex-China demand into partner income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eR-Pharm territory license\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSCYNEXIS, Inc. kept the R-Pharm territory license as an out-licensed geography, so development and commercialization spend sat with the partner, not SCYNEXIS, Inc. That makes the deal more cash-generative when the partner runs active work and sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOut-licensed geography\u003c\/li\u003e\n\u003cli\u003ePartner funds activity\u003c\/li\u003e\n\u003cli\u003eLower SCYNEXIS, Inc. burn\u003c\/li\u003e\n\u003cli\u003eCash flow improves with use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a BCG Cash Cow view, the value is steady fee or royalty-type economics, not heavy in-house spending. The main upside comes from partner-led execution, while SCYNEXIS, Inc. keeps capital needs light.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIBX patent estate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.'s ibrexafungerp patent estate is the cash-cow engine: the IP portfolio supports royalty income after the asset sale to GSK, so the value sits in monetization, not new R\u0026amp;D spend. Patent protection is what keeps that cash flow alive, and this is the classic cash-cow pattern when sales already exist. In SCYNEXIS, the IP base is the backbone for future royalty leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIP protects post-sale royalty streams\u003c\/li\u003e\n\u003cli\u003eCash flow comes from monetization\u003c\/li\u003e\n\u003cli\u003ePatent life drives leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSCYNEXIS: BREXAFEMME and Partners Drive Steady Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.'s Cash Cow profile rests on BREXAFEMME, partner royalties, and out-licensed geographies that convert existing assets into steady cash with limited new spend. The clearest supports are the $4 million Hansoh upfront, up to $67 million in milestones, and partner-funded development that keeps SCYNEXIS, Inc. burn lower.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow source\u003c\/th\u003e\n\u003cth\u003eKey cash data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBREXAFEMME\u003c\/td\u003e\n\u003ctd\u003eRecurring product sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHansoh deal\u003c\/td\u003e\n\u003ctd\u003e$4M upfront, up to $67M milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR-Pharm territory\u003c\/td\u003e\n\u003ctd\u003ePartner-funded spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSCYNEXIS, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact SCYNEXIS, Inc. BCG Matrix document you'll receive after purchase. The full file is the same professionally formatted version shown here—no demo content, no watermarks, and no hidden changes. Once purchased, it’s ready for immediate download, use, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy discovery pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, SCYNEXIS was concentrated in 1 real value driver: ibrexafungerp. The older discovery pipeline was not a major revenue source and looked like sunk-cost legacy work, with little sign of material new value. In BCG terms, this fits Dogs: low growth, weak strategic pull, and no clear path to meaningfully change the mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-cap commercialization burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.’s single-product model makes commercialization a dog-like cost center: launch SG\u0026amp;A, sales force buildout, and medical education spend can outrun product cash flow before scale kicks in. Until revenue grows enough to cover those fixed costs, every extra dollar spent on selling the drug pressures cash burn and weakens the BCG profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR-Pharm geopolitical exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR-Pharm adds clear execution risk because SCYNEXIS, Inc. depends on a Russia-linked partner in just 1 geopolitically exposed market. Even if the science is strong, sanctions, payment frictions, and trade limits can cut near-term commercial value. That makes the territory a weak contributor versus U.S. assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core service agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core service agreements in SCYNEXIS, Inc. fit the Dogs bucket because they support the business, but they do not usually create stand-alone growth or market share. These contract, legal, and admin tasks tend to consume time and cash while adding little revenue leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupport function, not growth engine\u003c\/li\u003e\n\u003cli\u003eHigh effort, low share impact\u003c\/li\u003e\n\u003cli\u003eBest kept lean and tightly managed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnapproved historical antifungal assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.’s unapproved historical antifungal assets are Dogs: they have no approved products, so they do not generate product revenue and keep consuming R\u0026amp;D capital. In 2025, the right call is usually to close, license, or divest these programs instead of funding more development. That frees cash for higher-probability assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approval means no sales.\u003c\/li\u003e\n\u003cli\u003eCash burn stays high.\u003c\/li\u003e\n\u003cli\u003eClosure or divestiture fits best.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSCYNEXIS Dog Assets: Cash-Hungry, Low-Return Legacy Holds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in SCYNEXIS, Inc. are the legacy and non-core assets: they absorb cash, add little growth, and have no clear path to scale. In 2025, the company still depended on 1 approved product, so older pipeline work stayed low-value and capital hungry. Weak share, weak growth, weak payoff.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy pipeline\u003c\/td\u003e\n\u003ctd\u003eNo approval, no sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-core services\u003c\/td\u003e\n\u003ctd\u003eCosts cash, little growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIbrexafungerp IV formulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSCYNEXIS is developing an intravenous ibrexafungerp for hospital use, where IV antifungals matter most for sicker patients with invasive infections. That keeps the asset in a large, high-need niche, but its BCG case is still a Question Mark because no commercial share is proven yet. Invasive candidiasis can carry mortality near 40% in hospitalized patients, so the upside is real if SCYNEXIS wins formulary uptake. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvasive aspergillosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInvasive aspergillosis is a high-need market, with reported mortality often around 30% to 50% in high-risk patients. SCYNEXIS is testing ibrexafungerp here as a future growth driver, so this fits a Question Mark: big need, but still uncertain proof and adoption. If it works, it could move Company Name beyond women’s health and into serious hospital infections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvasive candidiasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInvasive candidiasis is a question mark for SCYNEXIS, Inc.: the hospital market is large, but ibrexafungerp adoption is still not established. The disease carries severe risk, with invasive Candida infections showing mortality that can exceed 30% in bloodstream cases. If SCYNEXIS wins hospital uptake, this could become a high-growth revenue line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRefractory invasive fungal infections\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRefractory invasive fungal infections are a classic question mark for SCYNEXIS, Inc. The addressable pool is small, but the need is urgent: invasive candidiasis is estimated at about 25,000 U.S. cases a year, and mortality can exceed 40% in severe cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall market, high unmet need.\u003c\/li\u003e\n\u003cli\u003eStrong fit for novel antifungals.\u003c\/li\u003e\n\u003cli\u003eMedically important, but niche.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-U.S. ibrexafungerp expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-U.S. ibrexafungerp looks like a Question Mark: the franchise can grow beyond the U.S., but SCYNEXIS, Inc. depends on partners such as Hansoh to do the heavy lift. That keeps capital needs lower, yet makes revenue share and launch timing harder to predict. I’d treat it as promising, not proven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led, not SCYNEXIS-led.\u003c\/li\u003e\n\u003cli\u003eUpside depends on ex-U.S. execution.\u003c\/li\u003e\n\u003cli\u003eCommercial share is still uncertain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSCYNEXIS’ Hospital Upside: High-Risk, High-Reward\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSCYNEXIS, Inc.’s Question Marks are hospital ibrexafungerp uses: invasive candidiasis and invasive aspergillosis. The upside is real, but 2025 share is still unproven and uptake is not yet visible. Invasive candidiasis can carry 30%+ mortality, so even small formulary wins could matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCandidiasis mortality\u003c\/td\u003e\n\u003ctd\u003e30%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAspergillosis mortality\u003c\/td\u003e\n\u003ctd\u003e30%-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235010814217,"sku":"scyx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/scyx-bcg-matrix.webp?v=1785731060","url":"https:\/\/dcfanalyst.com\/products\/scyx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}